Atkins Diet and Prostate Cancer Clinical Trial
- Conditions
- Prostate Cancer
- Interventions
- Behavioral: Atkins Diet
- Registration Number
- NCT00932672
- Lead Sponsor
- Duke University
- Brief Summary
This study will test the hypothesis that a low-carbohydrate Atkins diet will prevent or at least minimize the metabolic consequences of androgen deprivation therapy (ADT).
- Detailed Description
Androgen deprivation therapy (ADT) is the standard treatment for advanced prostate cancer. While a very effective anti-cancer treatment, ADT is associated with significant toxicity including but not limited to major metabolic disturbances including impaired glucose tolerance, insulin resistance, and weight gain. We hypothesize that limiting carbohydrates within the diet will prevent or at least minimize these consequences.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Male
- Target Recruitment
- 45
- Histologically confirmed adenocarcinoma of the prostate
- Scheduled to initiate ADT with an anticipated duration of ≥ 6 months
- Overweight or obese (body mass index ≥ 25 kg/m2)
- Symptomatic metastatic disease
- Myocardial infarction within 6 months
- Treatment with medications known to affect insulin or glucose levels (i.e. insulin, oral hypoglycemics, prednisone, etc.)
- Patient consuming a low-carbohydrate diet
- Medical conditions or co-morbidities that preclude participation in the protocol
- Vegetarians
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Atkins group Atkins Diet Men assigned to the Atkins diet will be asked to restrict carbohydrate intake to \<20 grams/day. We will use an established clinical program directed by Dr. Eric Westman which implements this diet using a trained clinical nutritionist. No other dietary restrictions will be placed on the subjects. They will measure their urinary ketones at home weekly using urinary ketone strips. Subjects will meet with the nutritionist monthly during the 6 months of the study. Subjects in the Atkins arm will also be asked to walk at a brisk pace for 30 minutes a day, 5 days a week and will be provided a pedometer to measure the number of steps taken per day.
- Primary Outcome Measures
Name Time Method The primary end-point will be differences in insulin sensitivity between the arms 6 months
- Secondary Outcome Measures
Name Time Method Measures will include other cardiac risk factors, overall body morphometrics, body composition as assessed by dual energy x-ray absorptiometry (DXA), and cancer control (PSA levels) 6 months
Trial Locations
- Locations (3)
Greater Los Angeles VA Medical Center
🇺🇸Los Angeles, California, United States
Duke University Medical Center
🇺🇸Durham, North Carolina, United States
University of California, Los Angeles
🇺🇸Los Angeles, California, United States